Table 4.
Clinical efficacy of FDA-approved PD-L1 inhibitors
| PD-L1 inhibitors | Cancer type | Trial (Phase) | Patients(n) | ORR (%) | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
| Avelumab | Metastatic UC[151] | Ib | 44 | 18.2 | 2.9 | 13.7 |
| RCC[152] | III | 886 | 55.2 | 13.8 | 11.6 | |
| MCC[153] | II | 88 | 33.0 | - | 12.6 | |
| Atezolizumab | MUC[155] | II | 310 | 26.0 | 2.1 | 11.4 |
| NSCLC[154] | III | 1021 | 6.3 | 13.5 | - | |
| Durvalumab | NSCLC[156] | III | 713 | - | 14.5 | 25.2 |
| TNBC with PD-L1(+)[157] | II | 199 | - | - | 27.3 | |
| Cemiplimab | CSCC[158] | II | 78 | 44 | - | - |
| NSCLC[159] | I | 20 | 25.0 | - | - |
ORR objective response rate, mPFS median progression-free survival, mOS median overall survival